Drugs Directory & Medical Information

Multi-Specialty Protection from birth: Translating maternal RSV immunisation into clinical practice

Professor Dr Raman Subramaniam and Dato’ Dr Musa Mohd Nordin give their insights on respiratory syncytial virus (RSV) from obstetrics and gynaecology and paediatric perspectives, respectively. Here, they highlight how maternal RSV immunisation may help address an important gap in infant protection while raising important considerations regarding implementation, education, and access. RSV is a major cause of acute lower respiratory tract infection in infants and young children worldwide. Most infections are self-limiting, but RSV can cause severe bronchiolitis, pneumonia, hospitalisation and even death, especially in the first months of life. As awareness of RSV increases, and with preventive options becoming available, maternal immunisation is emerging as a viable strategy to protect infants during their most vulnerable stage.

18 Aug 2026

Multi-Specialty Singapore Specialists Discuss RSV Prevention Strategies

Two experts in their field, Dr Shephali Tagore and Clinical Associate Professor Yung Chee Fu, share their perspectives on maternal respiratory syncytial virus (RSV) immunisation, parental awareness gaps, and the practical realities of integrating prevention into clinical care pathways.

21 Jul 2026

Singapore Specialists Discuss
RSV Prevention Strategies

Infectious-Diseases Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

Protecting infants against RSV begins before birth. At a Pfizer-sponsored symposium during ESCMID Global 2026, experts reviewed the latest evidence on maternal RSV immunization, including disease burden, effectiveness, safety, and implementation. Presentations by Professors Marta Nunes, Paolo Manzoni, and Dr Olivia Anselem highlighted how maternal vaccination protects against severe RSV disease in early infancy. Professor Beate Kampmann chaired the session.

15 Jul 2026

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

Infectious-Diseases Tackling the increasing threat of MBL-producing pathogens and S. maltophilia: Key insights from ESCMID Global 2026

Antimicrobial resistance (AMR) continues to challenge healthcare systems worldwide, with carbapenem-resistant Gram-negative infections among the most urgent clinical threats. At a symposium held during ESCMID Global 2026, Dr Subramanian Swaminathan (India), Dr Paula Ramírez (Spain), Prof Gian Maria Rossolini (Italy), Prof Garyfallia Poulakou (Greece), and Prof Michele Bartoletti (Italy) explored the epidemiology, diagnosis, and management of infections caused by metallo-β-lactamase (MBL)-producing organisms, with a particular focus on carbapenem-resistant Enterobacterales (CRE) and Stenotrophomonas maltophilia.

13 Jul 2026